Cardiovascular safety and DPP-4 inhibitors

Practical Diabetes

Volumn 30, Issue 2, 2013, Pages 78-81

  Carty, David M ^a,b   Drummond, Russell ^a   Fisher, Miles ^a  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Cardiovascular outcomes; Cardiovascular safety; DPP 4 inhibitors

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALOGLIPTIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; LINAGLIPTIN; METFORMIN; PLACEBO; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA; VILDAGLIPTIN;

ACUTE CORONARY SYNDROME; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; DRUG APPROVAL; DRUG SAFETY; GLOMERULUS FILTRATION RATE; HEART INFARCTION; HUMAN; HYPOGLYCEMIA; INCIDENCE; LONG TERM CARE; META ANALYSIS (TOPIC); MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT SAFETY; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; UNSTABLE ANGINA PECTORIS;

EID: 84878275595     PISSN: None     EISSN: 20472900     Source Type: Journal    
DOI: 10.1002/pdi.1749     Document Type: Review

References (19)

1. NHS Scotland Scottish Diabetes Survey Monitoring Group (2011) Scottish Diabetes Survey. http://diabetesinscotland.org.uk.
2. Duckworth W, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360(2):129-39.
3. Gerstein HC, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358(24):2545-59.
4. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356(24):2457-71.
5. Patel A, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358(24):2560-72.
6. Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus. European Medicines Agency. www. ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2012/06/ WC500129256.pdf.
7. Guidance for Industry: Diabetes Mellitus-Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes. US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/%20Guidances/UCM071627.pdf.
8. Williams-Herman D, et al. Safety and tolerability of sitagliptin in clinical studies: A pooled analysis of data from 10,246 patients with type 2 diabetes. BMC Endocr Disord 2010;10:7.
9. Schweizer A, et al. Assessing the cardio-cerebrovascular safety of vildagliptin: Meta-analysis of adjudicated events from a large Phase III type 2 diabetes population. Diabetes Obes Metab 2010;12(6): 485-94.
10. Schweizer A, et al. Assessing the general safety and tolerability of vildagliptin: Value of pooled analyses from a large safety database versus evaluation of individual studies. Vasc Health Risk Manag 2011;7:49-57.
11. Frederich R, et al. A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes. Postgrad Med 2010;122(3):16-27.
12. Johansen OE, et al. Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: A pre-specified, prospective, and adjudicated metaanalysis of a phase 3 programme. Cardiovasc Diabetol 2012;11:3.
13. White W, et al. Cardiovascular events in patients receiving alogliptin: A pooled analysis of randomized clinical trials. American Diabetes Association Scientific Sessions 2010. Abstract 391-PP, 2010.
14. TECOS: A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes After Treatment With Sitagliptin in Patients With Type 2 Diabetes Mellitus and Inadequate Glycemic Control. http://clinicaltrials.gov/ show/NCT00790205.
15. Scirica BM, et al. The design and rationale of the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI) 53 study. Am Heart J 2011;162(5):818-25.
16. CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients with Type 2 Diabetes. http://clinicaltrials.gov/show/NCT01243424.
17. White WB, et al. EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): A cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome. Am Heart J 2011; 162(4):620-6.
18. Marney A, et al. Interactive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensinconverting enzyme inhibition in humans. Hypertension 2010;56(4):728-33.
19. Hocher B, et al. Renal and Cardiac Effects of DPP-4 Inhibitors-from Preclinical Development to Clinical Research. Kidney Blood Press Res 2012;36(1):65-84.